Nature vs. nurture: Rapidly assess the impact of cell culture conditions on mAb quality and production
Webinar Date/Time: Mon, Dec 4, 2023 11:00 AM EST
Gain critical information to make decisions in minutes. Rapidly assess the impact of cell culture conditions on mAb quality and production.
Register Free: https://www.biopharminternational.com/bp_w/charge-variant-identifications
Event Overview:
Biopharmaceutical product development is all about product knowledge, whether it be writing a regulatory submission, investigating unexpected results, or performing extended characterization. To ensure product safety and process consistency, it is critical to characterize and monitor charge variants according to regulatory and quality requirements. However, conventional approaches for these assays are time-intensive and often provide insufficient separation resolution.
In this webinar, we will discuss a new strategy to dramatically simplify charge variant characterization. Discover how you can gain multiple pieces of critical information early in process development to assess the impact of cell culture conditions on monoclonal antibody (mAb) quality and production.
Key Learning Objectives:
By attending this webinar, you will learn how to:
- Identify glycation at the intact protein level with the Intabio ZT system
- Maintain separation resolution between icIEF and mass spectrometry
- Implement icIEF/UV-MS during cell culture process development
Who Should Attend:
- Scientists in biotherapeutics development, especially in process development, cell line development, and formulations scientists
Speakers:
Greg Adams
Senior Director, Global Analytical Strategy & Development
FujiFilm Diosynth Biotechnologies
Greg Adams has 30 years of experience in analytical development, specializing in the mass spectrometric characterization of protein-based biopharmaceuticals. Greg has spent the majority of his career at FUJIFILM Diosynth Biotechnologies supporting the characterization and commercialization of biotherapeutic proteins. In his current role, he is responsible for strategic projects related to Fujifilm’s analytical service offerings, new analytical technologies, and industry collaborations.
Scott Mack
Senior Scientist
SCIEX
Register Free: https://www.biopharminternational.com/bp_w/charge-variant-identifications
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.
